Celltrion to supply rapid COVID-19 tests to US govt.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Celltrion announced Thursday that it had won a contract to supply its rapid COVID-19 test DiaTrust to the US government.
Starting Oct. 1, Celltrion USA, Celltrion’s US-based unit, will begin supplying COVID-19 tests to 25,000 sites, including military facilities, nursing homes and COVID-19 test centers.
Under the deal signed with the US Defense Logistics Agency, the US authorities could buy more if needed. Celltrion said the total amount could reach 738.2 billion won ($626.61 million), without disclosing the initial order.
Bloomberg reported that the deal was for 19 million DiaTrust tests for $626.4 million.
Celltrion said among companies that recently won US government contracts, it expected to be the largest supplier of rapid COVID-19 tests.
“It is meaningful that the company has won the US government contract, which asks to procure domestic materials and products under the Buy American Act.”
Celltrion’s DiaTrust is an antigen test co-developed by Celltrion and local biotech firm Humasis. The test won emergency use authorization from the US Food and Drug Administration in April.
The rapid COVID-19 test, which is used in medical settings, can return results in about 15 minutes on-site.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.